Category - Developments

Developments

Provention Bio begins Phase 3 trial of teplizumab for recent onset Type 1 diabetes

Provention Bio (NASDAQ:PRVB) has dosed the first patient in its Phase 3 clinical trial of teplizumab for Type 1 diabetes (T1D). The trial will determine whether teplizumab, an anti-CD3 monoclonal antibody, slows the...

April 9, 2019

Developments

Chembio’s test for Zika, dengue and chikungunya approved by Brazil health regulator

Chembio Diagnostics’ (NASDAQ:CEMI) Zika/dengue/chikungunya multiplex test has been approved by Brazil’s health regulatory agency, ANVISA. The test uses Chembio’s DPP technology platform to detect both active infection...

April 9, 2019

Developments

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

IntelGenx’s (TSX-V:IGX) (OTCQX:IGXT) Montelukast VersaFilm program received positive and constructive feedback from the scientific community at the 14thInternational Conference on Alzheimer’s & Parkinson’s Diseases...

April 8, 2019

Developments

Valeritas V-Go reports greater A1C reduction with 24% less daily insulin

Valeritas Holdings’ (NASDAQ:VLRX) V-Go wearable insulin delivery device significantly lowered Type 2 diabetes (T2D) patients’ average A1C levels, compared with those using standard insulin treatment. Valeritas’ V-GoAL...

April 8, 2019

Developments

Trovagene AML drug generates positive interim Phase 1b/2 data

Trovagene (NASDAQ:TROV) announced positive interim data from its Phase 1b/2 dose escalation trial of onvansertib, in combination with standard-of-care chemotherapy, in acute myeloid leukemia (AML) patients. Three of six...

April 5, 2019

Developments

SELLAS and top cancer center to study drug combination for mesothelioma

SELLAS Life Sciences Group (NASDAQ:SLS) and Memorial Sloan Kettering Cancer Center will conduct a Phase 1 study of SELLAS’ galinpepimut-S (GPS) in combination with nivolumab in patients with relapsed or refractory...

April 5, 2019

Developments

FDA accepts Homology’s IND for Phase 1/2 study of PKU gene therapy

Homology Medicines (NASDAQ:FIXX) received FDA clearance to commence its Phase 1/2 study of HMI-102 in adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU lack the...

April 5, 2019

Developments

Entasis initiates Phase 3 pivotal trial for drug-resistant infections

Entasis Therapeutics (NASDAQ:ETTX) has initiated a Phase 3 pivotal clinical trial to evaluate ETX2514 and sulbactam (ETX2514SUL) for the treatment of carbapenem-resistant A. baumannii infections. A. baumannii causes...

April 5, 2019

Developments

Profound Medical posts positive top line pivotal trial results in prostate cancer with TULSA-PRO

Profound Medical (TSX:PRN; OTCQX:PRFMF) reported positive top line results from the TACT pivotal study designed to support its application to the FDA for 510(k) clearance to market TULSA-PRO in the U.S. The TULSA-PRO...

April 5, 2019

Developments

IntelGenx among few Quebec companies leading cannabis edibles market

An article recently published in La Presse highlighted Montreal’s IntelGenx (OTCQX:IGXT; TSXV:IGX) as one of the few Quebec-based companies at the forefront of the cannabis edibles market. Of some 150 Health Canada...

April 3, 2019

Category - Developments

Provention Bio begins Phase 3 trial of teplizumab for recent onset Type 1 diabetes

Chembio’s test for Zika, dengue and chikungunya approved by Brazil health regulator

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

Valeritas V-Go reports greater A1C reduction with 24% less daily insulin

Trovagene AML drug generates positive interim Phase 1b/2 data

SELLAS and top cancer center to study drug combination for mesothelioma

FDA accepts Homology’s IND for Phase 1/2 study of PKU gene therapy

Entasis initiates Phase 3 pivotal trial for drug-resistant infections

Profound Medical posts positive top line pivotal trial results in prostate cancer with TULSA-PRO

IntelGenx among few Quebec companies leading cannabis edibles market

General

More